Analysts See $-0.47 EPS for Nightstar Therapeutics plc (NITE)

August 13, 2018 - By Carol Mulligan

Analysts expect Nightstar Therapeutics plc (NASDAQ:NITE) to report $-0.47 EPS on September, 5.After having $-0.52 EPS previously, Nightstar Therapeutics plc’s analysts see -9.62 % EPS growth. The stock decreased 6.15% or $1.1 during the last trading session, reaching $16.8. About 69,928 shares traded. Nightstar Therapeutics plc (NASDAQ:NITE) has 0.00% since August 13, 2017 and is . It has underperformed by 12.57% the S&P500.

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company has market cap of $375.28 million. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It currently has negative earnings. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.